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Abstract
Stereotactic body radiotherapy (SBRT) has emerged as an effective option in oligo-metastatic cancer patients affected by 
lymph node metastases, but its use might be questioned due to risk of regional and distant dissemination through the lymph 
node chain. The primary aim of our study was to assess the loco-regional control following SBRT in this setting. Ninety-
one patients undergoing SBRT for at least one lymph node metastasis from miscellaneous primary tumors were retrospec-
tively evaluated for patterns of failure and toxicity. locoregional relapse-free survival (LRRFS) and distant metastasis-free 
survival (DMFS) at 4 years were 79 and 44%. Repeated use of local therapy after progression resulted in a median interval 
of 17 months until allocation to systemic therapy or supportive care. Forty-three percent of patients were alive at 4 years. 
Local failure, occurring in 15% of patients, was the only predictor of poor survival (HR: 3.06). Tumor diameter ≥ 30 mm and 
urothelial primary tumor predicted for impaired local control (HR: 4.59 and 5.43, respectively). Metastases from pulmonary 
cancer showed a significant earlier distant dissemination (HR: 3.53). Only acute and late grade 1–2 toxicities were reported 
except for 1 case of G3 dysphagia. Loco-regional failure risk is low (18%) and justifies the use of local therapies for patients 
with oligometastatic disease. Durable disease remission can be achieved by iterative use of local approaches. Local control 
is correlated to improved OS. Diameter and primary tumor type may affect response to SBRT and risk for early metastatic 
dissemination.
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Abbreviations
LF  Local failure
LRF  Loco-regional failure
DM  Distant metastases
DP  Disease progression
LC  Local control
LRRFS  Loco-regional relapse-free survival
DMFS  Distant metastasis-free survival
DFS  Disease-free survival
OS  Overall survival
cDFS  Corrected disease-free survival
SBRT  Stereotactic body radiotherapy
OARs  Organs at risk
GTV  Gross tumor volume
PTV  Planned tumor volume
BED  Biologically effective dose
Introduction
Since the formulation of the concept of oligo-metastatic dis-
ease by Hellman in 2005, the existence of an intermediate 
condition between organ-confined and extensively dissemi-
nated malignancy has been debated. Indeed, loco-regional 
treatment by surgery or radiotherapy might be proposed to 
metastatic cancer patients with limited disease burden (3–5 
metastases) [1] to avoid or postpone the use of chemotherapy 
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[2]. This new paradigm of treatment integrated clinical prac-
tice in a number of different settings, such as limited liver or 
lung metastatic involvement from operated primary tumors 
[3–5], but it is unclear whether this policy could be benefi-
cial in all cases. In particular, appropriate management of 
isolated lymph node metastasis often result in a dilemma for 
the clinician due to the high risk of subclinical dissemina-
tion along the node chain [6]. In recent years, stereotactic 
body radiotherapy (SBRT) emerged as a valuable option in 
the treatment of oligo-metastatic patients, delivering abla-
tive radiation doses with limited toxicity, but the level of 
evidence for its applicability in the management of lymph 
node relapse is still poor. Initial reports showed satisfying 
local control rates with good to excellent survival, but there 
is a lack of information on the patterns of disease progres-
sion following SBRT [7]. Therefore, the primary aim of 
the study was to investigate the locoregional relapse-free 
survival. Secondary objectives were to investigate general 
outcome and predictors of disease control in a cohort of 
oligo-metastatic patients undergoing SBRT for lymph node 
metastases of treated primary tumors.
Materials and methods
Patient selection, treatment procedures 
and follow‑up
Ninety-one consecutive patients with oligo-metastatic lymph 
node metastasis were treated at our Institution between May 
2005 and September 2016 with stereotactic radiotherapy 
after curative treatment of the primary tumor. Indication to 
treatment was discussed at Multidisciplinary Tumor Board. 
Criteria for inclusion were oligo-metastatic lymph node 
metastasis with ≤ 3 metastases in two organs, considering 
the nodal drainage as one organ. Stereotactic treatment was 
performed using the Cyberknife radiotherapy system. Plan-
ning treatment volume (PTV) was obtained by isotropic 
expansion of 2–5 mm around the GTV (median 3 mm). The 
total dose was prescribed to the outer line of the PTV and 
was prescribed to the 75–85% isodose line using different 
fractionated schedules. Dose constraints for organs at risk 
(OARs) were applied according to the American Associa-
tion of Physicists in Medicine (AAPM) recommendations 
[8]. Clinical evaluation with physical examination and CT-
scan was performed at 3 and 6 months, and subsequently 
once a year until 5 years after the treatment or until disease 
progression. Assessment of efficacy and acute and late tox-
icity (within or after after 3 months from the end of treat-
ment, respectively) was retrospectively performed using 
the revised response evaluation criteria in solid tumors 
(RECIST version 1.1, 2009) and the Common Terminology 
Criteria for Adverse Events (CTCAE version 4.03, 2010), 
respectively.
Definition of the endpoints
Local failure (LF) was defined as an increase of at least 20% 
in diameter of the treated volume. Loco-regional failure 
(LRF) was defined as onset of one or more metastases in the 
same anatomical chain of the treated lymph node but outside 
the PTV. Distant metastases (DM) were defined as metas-
tases occurring outside the anatomical chain of the treated 
lymph node. Any of the above cited events (LF, LRF, DM) 
when occurring for the first time after SBRT was considered 
as disease progression (DP). Local control (LC) was calcu-
lated from the start of radiation therapy to the date of LF. 
Loco-regional relapse-free survival (LRRFS), distant metas-
tasis-free survival (DMFS) and disease-free survival (DFS) 
were measured from start of radiation therapy to occurrence 
of LRF, DM and DP, respectively. A corrected DFS (cDFS) 
was calculated as a surrogate indicator of chemotherapy-free 
survival as followed: local and/or distant progression effec-
tively treated by a local curative approach such as surgery 
or SBRT was censored until the patient developed a new 
metastasis requiring systemic treatment or supportive care 
or until patient’s death. Overall survival (OS) was meas-
ured from start of the radiation therapy until death from any 
cause. Patients who did not experience any of the above-
cited events were censored on the last day of contact.
Statistical analysis
Statistical analysis was performed with IBM SPSS v.21 sta-
tistical software. We applied the Kaplan–Meier method to 
estimate survival curves and used the log-rank test to com-
pare curves between levels of the following dichotomized 
categorical and continuous (cut-off: median value) variables: 
gender, age, primary tumor type (colorectal, lung, urothelial, 
cervical), use of 18-FDG-PET, diameter, biologically effec-
tive dose for α/β = 10 (BED), prior use of chemotherapy. A 
multivariable Cox regression analysis was performed includ-
ing all risk factors with a p value of < 0.2 in the univariable 
analysis. Logistic regression was performed to test relation-
ship between tumor diameter and LC. A p-value ≤ 0.05 was 
considered statistically significant.
Results
Baseline characteristics
Eighty-seven patients (96%) were referred with an isolated 
lymph node metastasis; four patients presented with a metas-
tasis in a lymph-node and in another organ (brain, lung and 
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liver in respectively 1, 1 and 2 patients). All patients under-
went a Chest-Abdomen CT, while a restaging 18-FDG-PET 
was performed in 36 (39%) patients.
Thirty-five percent of these patients were previously 
treated with chemotherapy, 13% with surgery or SBRT for 
another metastasis, and in 52% no treatment had yet been 
given for the metastasis. Lymph node biopsy was collected 
in 48 patients (52%) while pathological diagnosis from 
a metastasis in another site was available in 14 out of 43 
patients. Among the other 29 patients, nine underwent a 
restaging 18-FDG-PET following serum marker increase, 
while decision for treatment in the remaining 20 patients 
was based on progression on two CT scans due to technically 
infeasible procedure or refusal of the patient. Median diam-
eter (defined as the maximum axial dimension as measured 
on planning CT scan) was 30 mm (5–63 mm). A fractiona-
tion scheme delivering a BED ≥ 75 Gy10 was used in 87% 
of patients.
Patient and treatment-related data are summarized in 
Table 1.
Patterns of failure and treatment at progression
After a median follow-up of 23.3 months, 14 local failures, 
16 locoregional relapses and 46 distant metastases were 
reported. At the time of our analysis, 56 patients experienced 
disease progression following SBRT: among them, disease 
progression was limited to ≤ 3 metastases in 32 patients, 
allowing for continuation of local treatments in 13 patients. 
Patterns of failure and treatment at progression are resumed 
in Table 2.
Treatment outcome and patterns of care
Median follow-up after SBRT was 23.3  months (range 
1.0–138.9, Inter-Quartile Range 9.9–42.3).
LRRFS was 79% at both 2 and 4 years (Fig. 1b): no pre-
dictive factor for relapse in neighboring lymph nodes was 
found at statistical analysis. Distant metastasis-free survival 
was 51% at 2 year and 44% at 4 years (Fig. 1c). Median time 
to metastatic failure was 26 months (95% CI 7–56). Pri-
mary lung cancer was the only predictor of impaired DMFS 
at both univariate (p = 0.015) and multivariate analysis 
(p = 0.02, HR: 2.65 [95% CI 1.17–6.02]).
Two- and 4-years OS were 65 and 43%, respectively 
(Fig. 1f). Median overall survival was 36 months (95% CI 
22–50). Lung primary, diameter ≥ 30 mm and LC were pre-
dictors of impaired survival at univariate analysis (p = 0.049, 
0.029 and 0.001, respectively). However, only LC confirmed 
its predictive value at multivariate analysis (p 0.01, HR: 3.06 
[95% CI 1.53–6.14]) (Fig. 2a).
DFS was 35% at 2 years and 31% at 4 years (Fig. 1e). 
Median time to disease progression was 13 months (95% CI 
8–18). At univariate analysis, lung carcinoma (p = 0.006) 
and diameter ≥ 30 mm(p = 0.048) were significantly associ-
ated to disease progression. The predictive value of both 
lung primary and diameter (p = 0.01, HR: 2.69 [95% CI 
1.27–5.73]; p = 0.048, HR: 1.71 [95% CI 1.00–2.90]) was 
confimed by multivariate analysis.
The 2 and 4-years cDFS were 46 and 35%, respectively 
(Fig. 1d). Median cDFS was 17 months (95% CI 5–28). 
Lung primary and diameter ≥ 30 mm were confirmed the 
main determinants of cDFS at both univariate (p = 0.01 and 
p = 0.02, respectively) and multivariate analysis (p = 0.01, 
HR: 2.59 [95% CI 1.21–5.57]; p = 0.02, HR: 1.71 [95% CI 
1.10–3.26]) (Fig. 2b, c).
Concerning local control of the irradiated metastasis, 2 
and 4-years LC was 78% (Fig. 1a). At univariate analysis, 
urothelial malignancy (p = 0.022) and diameter ≥ 30 mm 
(p = < 0.001) were correlated with impaired local control. 
Multivariate analysis confirmed that both urothelial ori-
gin (p = 0.015, HR: 5.43 [95% CI 1.42–20.84]) and diam-
eter ≥ 30 mm (p = 0.013, HR: 4.59 [95% CI 1.41–14.95]) 
were independent risk factors for local failure (Fig. 2d-e). In 
a logistic regression model, a significant correlation between 
diameter and local failure was observed (p = 0.02) resulting 
in an increase in the odds for local failure failure by 1.053 
[95% CI 1.011–1.096] for every 1 mm increase in diameter 
(Fig. 3).
Treatment‑related toxicity
Acute toxicity consisted mainly of mild Grade 1–2 nau-
sea and diarrhea; exacerbation of pain and dysphagia were 
observed in a minority of patients. Symptoms required 
medical intervention in less than half of patients. Severe 
G3 dysphagia was reported in one patient that underwent 
feeding tube positioning during the SBRT course; symptoms 
spontaneously regressed after 1 week.
Focusing on late toxicity, no G3 toxicity was observed; 
the most common symptom following SBRT was mild 
G1-G2 chronic pain requiring no intervention or medication. 
No treatment-related death were observed in our cohort. 
Toxicities are reported in Table 3.
Discussion
The hypothesis of our study is that focal treatment by SBRT 
in oligometastatic patients experiencing limited nodal 
relapse might be effective in arresting spread to the locore-
gional drainage and ultimately metastatic dissemination, 
irrespectively of patient baseline characteristics, prior treat-
ments and primary tumor type. To test these hypothesis we 
reviewed a large consecutive serie of oligometastatic patients 
receiving SBRT for lymph nodal relapse after discussion at 
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the Multidisciplinary Tumor Board for miscellaneous tumor 
types at different time points in the treatment sequence.
We reported the patterns of disease progression, in par-
ticular, early relapse to neighboring lymph nodes located 
on the same chain. This event occurred in the majority of 
patients at the same time of metastatic relapse to one or 
more extra-node districts, thus conferring theoretically no 
additional benefit to a more aggressive alternative approach 
encompassing the whole lymphatic drainage. On the other 
hand, selected patients who ultimately experience progres-
sion in proximity of the treated metastasis could still benefit 
from repeated SBRT or surgery in 25%. Therefore, onset of 
loco-regional relapse should not be considered as the result 
of inappropriate allocation to SBRT of patients that should 
have received upfront chemotherapy and should not influ-
ence the decision to perform further local therapies to pro-
long the systemic therapy free-interval, whenever feasible.
It is noteworthy that our report shows an impact of 
response to SBRT on survival in patients receiving SBRT for 
lymph node metastases, supporting the rationale of reduc-
ing the gross disease burden in oligo-metastatic patients by 
local approaches to improve outcome and alter the natural 
course of the disease. Most notably, after a median follow 
up of 23 months, 35% of patients did not experience any 
disease progression, suggesting that a curative perspective 
can be undertaken in selected patients in accordance with 
proposed modeling of oligo-metastatic disease [17]: future 
studies should identify this subset of long-lasting respond-
ers that might benefit from an exclusive local approach to 
maximize therapeutic ratio and avoid overtreatment.
In our study, SBRT resulted in durable disease remission, 
and its use in a strategy encompassing repeated use of local 
treatments for limited-extent relapse allowed to postpone the 
administration of systemic therapy in 46% of the patients 
Table 1  Clinico-pathological 
and treatment-related features of 
the study population
Gender N %
Male
Female
36
55
39%
61%
Median age (years) 62 (28-83)
Prior treatment for metastac relapse N %
No
Local
Chemotherapy
47
12
32
52
13
35
Primary  Tumor N %
Colorectal
Urothelial
Non-Small Cell Lung
Ovarium
Cervix
Endometrium
Clear Renal Cells
Other
26
9
8
8
12
6
5
17
29
10
9
9
13
6
5
19
Lymph node chain N %
Para-aorc
Upper abdominal (truncus celiacus,portal, mesenteric vessels)
Pelvic (common/internal/external iliac, obturatory, presacral)
Supra-clavicular
55
6
28
2
60
7
31
2
PET restaging before SBRT N %
Yes
No
36
55
39%
61%
Number of metastasis at presentaon N %
Single node metastasis
Single node+ 1 extranodal metastasis
Single node+ 2 extranodal metastases
87
3
1
96
3
1
Median max diametre (mm) 30 (5-63)
Fraconaon schedule N %
48 Gy in 6 fracons
45 Gy in 5 fracons
42 Gy in 6 fracons
40 Gy in 5 fracons
Other fraconaon
50
27
4
4
6
55
30
4
4
7
Median BED10 ( α/β=10) 86 (53-113)
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for 2 years. Analysis of patterns of failure showed the value 
of target diameter and primary tumor as predictors of early 
local and distant failure, providing elements for selection of 
candidate patients for SBRT in the event of oligo-metastatic 
node involvement.
Lymph node metastases from solid cancers are a frequent 
occurrence in extensive metastatic dissemination due to the 
propensity of cancer cells to spread through the lymphatic 
drainage, often determining in-transit metastases [6]. How-
ever, in case of limited or isolated metastatic lymph-node 
involvement, therapeutic decision should consider the risk 
Table 2  Patterns of failure and 
treatment at secondary relapse 
following SBRT
Patterns of failure N Treatment at progression
BSC Local treat-
ment
Chemotherapy
Overall progression after SBRT 56 (62%) 13 15 28
 ≤ 3 metastases 32 (35%) 5 13 14
 > 3 metastases 24 (26%) 8 2 14
Local progression 14 (15%) 5 2 7
Locoregional lymph node relapse 16 (17%) 4 4 8
 Isolated relapse 3 (3%) 1 0 2
 Concurrent distant metastases 13 (14%) 3 4 6
Distant metastases 46 (50%) 9 13 24
Fig. 1  Kaplan Meyer curve (in years) for LC (a), LRRFS (b), DMFS (c), DFS (d), cDFS (e), and OS (f)
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of subclinical invasion of neighboring lymph-nodes. For 
this reason, treatment options in the event of isolated node 
metastasis from miscellaneous primary tumors traditionally 
encompass the entire drainage, ranging from surgical lym-
phadenectomy to upfront systemic treatment : irradiation of 
the node chain with or without boost to the macroscopic site 
of disease has also been proposed [10–14]. However, several 
limitations must be taken into account: efficacy of chemo-
therapy can be limited depending on the primary tumor; 
lymphadenectomy can be contra-indicated due to disease 
extent, involvement of critical structures and operative mor-
bidity; node chain irradiation may result in over-irradiation 
of critical structures, chronic lymphedema, and suboptimal 
efficacy due to the impossibility to the deliver high doses to 
an extended volume [10–14]. Moreover, according to the 
oligo-metastatic model, cancer cell spread might occur on 
a time-dependent, step-wise fashion, thus limited manage-
ment of the clinically evident metastasis might be sufficient 
to obtain durable disease control and might exert an effect on 
overall survival by reducing the amount of actively replicat-
ing cells in the metastatic niche [15].
For these reasons, stereotactic body radiotherapy (SBRT) 
limited to macroscopic lymphadenopathies has been inves-
tigated by a number of authors, reporting promising results 
in terms of 1-years local control > 90% [16–22], optimal 
symptom control [22], long systemic therapy-free interval 
[21] and the possibility to iteratively perform SBRT in case 
of limited secondary relapse [19, 23]. Nevertheless, toxicity 
reports and lack of data regarding distant failure and impact 
on survival, raised doubts about the efficacy of this strategy 
[24].
Fig. 2  Kaplan Meyer curves for OS according to local failure (dashed 
line) versus local control (solid line), p = 0.001 (a); cDFS accord-
ing to pulmonary (dashed line) versus non-pulmonary (solid line) 
primary, p = 0.01 (b); cDFS according to diameter ≥ 30 mm (dashed 
line) versus ≥ 30 (solid line), p = 0.02 (c); LC according to diam-
eter ≥ 30 mm (dashed line) versus ≥ 30 (solid line), p < 0.001 (d); LC 
according to urothelial (dashed line) versus non-urothelial (solid line) 
primary p = 0.02 (e)
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It is noteworthy that in our cohort, following SBRT, dis-
ease progression was limited to ≤ 3 metastases in 32 out 
of 56 patients. This resulted in a further local treatment in 
almost one-third of these 32 patients as is shown in Table 2. 
Other authors had similar results [19, 23]. However, this 
strategy has been applied only in a minority of patients who 
maintained an oligo-metastatic pattern after disease progres-
sion: therefore patients possibly eligible for further SBRT 
or surgery might have been prematurely allocated to chemo-
therapy, which means we probably underestimate the theo-
retical benefit of a strategy based on multiple local therapy 
courses.
Local control rates at 2 and 4 years were in line with pre-
viously published reports [16–21]. As previously described 
in liver oligometastases [25], the main determinant of local 
efficacy was axial diameter of the metastasis, that is a known 
surrogate for volume [26] : this information might provide 
an useful tool to select patients eligible for SBRT, since 
according to our logistic regression model the risk of failure 
increase up to one-third for a diameter > 50 mm, and stresses 
the importance of timing of SBRT in order to avoid treat-
ment delays that could profit tumor growth. Conversely, no 
impact of prior treatment (and by consequence of the time 
of onset of metastases in the natural history of the disease) 
was observed.
No treatment schedule corresponded to an advantage in 
terms of local efficacy: it could be argued that the use of 
high  BED10 ≥ 75 Gy in the majority of cases did not allow a 
comparison between patient groups [27].
Toxicity was acceptable, with only one G3 acute event. 
Hoyer et al. [28] reported a treatment-related death and two 
bowel perforations in a mixed cohort of patients treated for 
abdominal metastases using a three-fraction schedule: in 
our study the use of 5–6 fractions schedules, predominant 
para-aortic localization, frequent use of tracking devices and 
acceptance of rigid dose constraints to the OARs may have 
contributed to the low toxicity rate.
Our study suffers from the usual limitations of retrospec-
tive studies, in particular possible presence of confounders 
and recall bias in the retrospective collection of outcome and 
toxicity data. Stereotactic radiotherapy in our cohort was the 
upfront treatment for metastasis in 52% of cases. Previously 
published series reported the use of SBRT after a first-line 
systemic therapy in 38–80% of cases [16–21]: promising 
outcome data may be influenced by inclusion of patients at 
an early time point of cancer natural history. Despite signifi-
cant correlation was found between tumor diameter and risk 
of local failure, our logistic regression model was based on 
a small number of events and deserve further validation on 
larger series. The limited sample and the heterogeneity of 
treatment at progression do not allow to identify an optimal 
treatment sequence, in particular for patients with specific 
tumor types at higher risk of local failure or early distant 
dissemination. Due to retrospective evaluation of toxicity, 
underestimation or under-reporting of adverse events might 
not be excluded.
Fig. 3  Solid line express the correlation between diameter (mm) and 
failure probability after SBRT. Dashed line 95% Confidence Inter-
val. Black dot patients maintaining local control at the irradiated site. 
White dots patients experiencing local failure after SBRT
Table 3  Acute and late toxicity Acute Toxicity Overall G1 G2 G3
Dyspnea
Pain
Skin Reacon
Diarrhea
Nausea
Dysuria
Dysphagia
1
9
1
10
12
2
5
1
6
1
6
6
2
4
0
3
0
4
6
0
0
0
0
0
0
0
0
1
Late Toxicity Overall G1 G2 G3
Diarrhea
Pain
Dysuria
3
6
1
3
2
0
0
4
1
0
0
0
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Conclusions
After SBRT for lymph node metastases, the locoregional 
relapse free survival was 79% at 4 years. The overall sur-
vival was high (43% at 4 years) and it was correlated to 
local control after SBRT. Local therapies such as surgery or 
SBRT to new metastasis diagnosed after the SBRT allowed 
to postpone systemic therapies for 2 years in 46% of the 
patients. Diameter and type of primary tumor were cor-
related with risk of local and distant failure and might be 
taken into account in the clinical decision to perform SBRT. 
Hence, our results provided useful data for designing future 
studies on appropriate selection of candidate patients for 
this approach.
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